These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 35785170)

  • 1. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
    Mekonnen N; Yang H; Shin YK
    Front Oncol; 2022; 12():880643. PubMed ID: 35785170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer.
    Zhao Q; Bai L; Tan Y; Qie M
    Front Oncol; 2024; 14():1435029. PubMed ID: 39104720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
    Pacheco-Barcia V; Muñoz A; Castro E; Ballesteros AI; Marquina G; González-Díaz I; Colomer R; Romero-Laorden N
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740616
    [No Abstract]   [Full Text] [Related]  

  • 4. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
    Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
    Kyle S; Thomas HD; Mitchell J; Curtin NJ
    Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
    Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
    Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
    Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
    Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low testing rates and high
    Syed N; Chintakuntlawar AV; Vilasini D; Al Salami AM; Al Hasan R; Afrooz I; Uttam Chandani K; Chandani AU; Chehal A
    World J Clin Oncol; 2024 Jul; 15(7):848-858. PubMed ID: 39071455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAD51-Mediated DNA Homologous Recombination Is Independent of
    Sinha A; Saleh A; Endersby R; Yuan SH; Chokshi CR; Brown KR; Kuzio B; Kauppinen T; Singh SK; Baker SJ; McKinnon PJ; Katyal S
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA; Irshad S; Grigoriadis A; Tutt AN
    Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Recombination Repair Deficiency: An Overview for Pathologists.
    Doig KD; Fellowes AP; Fox SB
    Mod Pathol; 2023 Mar; 36(3):100049. PubMed ID: 36788098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers.
    Alhusaini A; Cannon A; Maher SG; Reynolds JV; Lynam-Lennon N
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous base damage as a driver of genomic instability in homologous recombination-deficient cancers.
    Aubuchon LN; Verma P
    DNA Repair (Amst); 2024 Sep; 141():103736. PubMed ID: 39096699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Determinants of Homologous Recombination Deficiency across Human Cancers.
    Qing T; Wang X; Jun T; Ding L; Pusztai L; Huang KL
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
    Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
    PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [BRCA1 and BRCA2 - pathologists starting kit].
    Škapa P
    Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.